betaxolol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 356 63659-18-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • betaxolol
  • (+/-)-Betaxolol
  • betaxolol hydrochloride
  • betaxolol HCl
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
  • Molecular weight: 307.43
  • Formula: C18H29NO3
  • CLOGP: 2.32
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 50.72
  • ALOGS: -4.01
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.45 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 15 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.17 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 17 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 30, 1985 FDA ALCON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stevens-Johnson syndrome 50.70 25.43 24 2229 23273 46660536
Limb injury 48.74 25.43 22 2231 19152 46664657
Fall 45.92 25.43 67 2186 329030 46354779
Hyperaesthesia 40.60 25.43 15 2238 7841 46675968
Transient ischaemic attack 36.31 25.43 22 2231 34881 46648928
Wound 34.60 25.43 23 2230 42779 46641030
Bradycardia 33.91 25.43 27 2226 66271 46617538
Acquired haemophilia 33.52 25.43 8 2245 923 46682886
Haemorrhage 31.65 25.43 24 2229 54845 46628964
Status epilepticus 29.17 25.43 14 2239 13965 46669844
Glaucoma 27.44 25.43 14 2239 15907 46667902
Angioplasty 26.26 25.43 7 2246 1260 46682549
Choking 25.77 25.43 11 2242 8365 46675444
Peripheral vascular disorder 25.77 25.43 10 2243 5967 46677842
Low density lipoprotein increased 25.73 25.43 10 2243 5990 46677819
Crepitations 25.58 25.43 10 2243 6082 46677727

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Wrong drug 42.12 26.48 6 807 67 29951598
Splenic rupture 34.14 26.48 8 805 1528 29950137

Pharmacologic Action:

SourceCodeDescription
ATC C07AB05 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, selective
ATC S01ED02 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Beta blocking agents
ATC S01ED52 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Beta blocking agents
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
CHEBI has role CHEBI:35530 beta-adrenoceptor antagonists
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:66991 sympatholytics
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D058671 Adrenergic beta-1 Receptor Antagonists
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013565 Sympatholytics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Hypertensive disorder indication 38341003 DOID:10763
Open-angle glaucoma indication 84494001 DOID:1067
Malignant glaucoma off-label use 10100008
Aphakic glaucoma off-label use 15374009
Secondary glaucoma off-label use 95717004
Bronchospasm contraindication 4386001
Psoriasis contraindication 9014002 DOID:8893
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Depressive disorder contraindication 35489007
Anaphylaxis contraindication 39579001
Chronic heart failure contraindication 48447003
Sinus bradycardia contraindication 49710005
Acute nephropathy contraindication 58574008
Diabetes mellitus contraindication 73211009 DOID:9351
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Asthma contraindication 195967001 DOID:2841
Heart block contraindication 233916004
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Pheochromocytoma contraindication 302835009
Acute exacerbation of asthma contraindication 708038006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Kd 8.80 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Kd 7.20 WOMBAT-PK
Beta-2 adrenergic receptor GPCR IC50 6.18 CHEMBL
Beta-2 adrenergic receptor GPCR Kd 6.98 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 8.76 CHEMBL

External reference:

IDSource
O0ZR1R6RZ2 UNII
4019633 VUID
N0000147726 NUI
D00598 KEGG_DRUG
63659-19-8 SECONDARY_CAS_RN
4018588 VANDF
4019633 VANDF
C0005320 UMLSCUI
CHEBI:3082 CHEBI
CHEMBL423 ChEMBL_ID
CHEMBL1691 ChEMBL_ID
DB00195 DRUGBANK_ID
D015784 MESH_DESCRIPTOR_UI
4530 INN_ID
2369 PUBCHEM_CID
549 IUPHAR_LIGAND_ID
142144 RXNORM
31545 MMSL
4280 MMSL
d00176 MMSL
001859 NDDF
004743 NDDF
349900007 SNOMEDCT_US
387195001 SNOMEDCT_US
409276006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Betoptic S HUMAN PRESCRIPTION DRUG LABEL 1 0065-0246 SUSPENSION/ DROPS 2.80 mg OPHTHALMIC NDA 25 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-623 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-624 TABLET, FILM COATED 20 mg ORAL ANDA 19 sections
BETAXOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10702-013 TABLET, COATED 10 mg ORAL ANDA 12 sections
BETAXOLOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10702-014 TABLET, COATED 20 mg ORAL ANDA 12 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 17478-705 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 19 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 24658-700 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 24658-701 TABLET, FILM COATED 20 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 42806-038 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 42806-039 TABLET, FILM COATED 20 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 54868-4932 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 60429-753 TABLET, FILM COATED 10 mg ORAL ANDA 12 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 60429-753 TABLET, FILM COATED 10 mg ORAL ANDA 12 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 60429-754 TABLET, FILM COATED 20 mg ORAL ANDA 12 sections
Betaxolol HUMAN PRESCRIPTION DRUG LABEL 1 60429-754 TABLET, FILM COATED 20 mg ORAL ANDA 12 sections
Betaxolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 61314-245 SOLUTION/ DROPS 5.60 mg OPHTHALMIC NDA authorized generic 19 sections